At the start of the COVID-19 pandemic, hopes were pinned on vaccines achieving herd immunity and eventually wiping out the SARS-CoV-2 virus. But, as the virus quickly evolved, it became clear that this was not going to happen — the most vulnerable would need antiviral drugs to fall back on. The first generation of these antivirals enjoyed some success but have come with complications. Now, three years on, with COVID-19 still a leading cause of death in many parts of the world, there is a new generation of antivirals around the corner.
展开▼
